Ponatinib (AP24534)

For research use only. Not for use in humans.

製品コードS1490

CAS No. 943319-70-8

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively. Ponatinib (AP24534) inhibits autophagy.

サイズ

価格(税別)

在庫

10mM (1mL in DMSO)	JPY 18600	あり
10mg	JPY 20200	あり
50mg	JPY 63400	あり
200mg	JPY 163000	あり

最寄りの販売代理店を探す

東京
北海道
東北
北関東
南関東
東海
北信越
近畿
中国
四国
九州

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください：[email protected]

バルク問合せ

代表番号: 03-5615-9297 | 電子メール：[email protected]

文献中Selleckの製品使用例(132)

製品安全説明書

Bcr-Abl阻害剤の選択性比較

生物活性

製品説明

ターゲット

Abl ^[1] (Cell-free assay)	PDGFRα ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)	FGFR1 ^[1] (Cell-free assay)	c-Src ^[1] (Cell-free assay)	もっとクリックする
0.37 nM	1.1 nM	1.5 nM	2.2 nM	5.4 nM	もっとクリックする

体外試験

AP24534 potently inhibits native Abl, Abl^T315I, and other clinically important Abl kinase domain mutants with IC50 of 0.30 nM–2 nM. AP24534 doesn't inhibit Aurora kinase family members, nor does it inhibit insulin receptor or CDK2/cyclin E. AP24534 inhibits proliferation of Ba/F3 cells expressing Bcr-Abl with IC50 of 0.5 nM, as well as Ba/F3 cells expressing a range of Bcr-Abl mutants with IC50 of 0.5 nM–36 nM. The inhibition of proliferation by AP24534 is correlated with induction of apoptosis. ^[1-2] In leukemic cell lines containing activated forms of FLT3, KIT, FGFR1, and PDGFRα receptors, AP24534 potently inhibits receptor phosphorylation and cellular proliferation with IC50 of 0.3 nM to 20 nM. In MV4-11 (FLT3-ITD(+/+)) but not RS4;11 (FLT3-ITD(–/–)) AML cells, AP24534 inhibits FLT3 signaling and induced apoptosis at less than 10 nM. AP24534 inhibits viability of primary leukemic blasts from a FLT3-ITD positive AML patient with IC50 of 4 nM but not those from patients with AML expressing native FLT3. ^[3] In Ba/F3 cells engineered to express activated FGFR1-4, AP24534 potently inhibits FGFR-mediated signaling and viability with IC50 lower than 40 nM. In cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon), and containing FGFRs dysregulated by a variety of mechanisms, AP24534 inhibits FGFR-mediated signaling with IC50 less than 40 nM and inhibits cell growth with IC50 of 7 nM–181 nM. ^[4]

細胞データ

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	NYGzT\|J5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXixXmFvUUN3ME2wMlAxODByMECzOVkh\|ryP	NVm1[21iW0GQR1XS
MV-4-11	M3HwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwMECwNFk2PiEQvF2=	MULTRW5ITVJ?
MEG-01	MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILBbnJKSzVyPUCuNFAxOTJ6IN88US=>	MkCyV2FPT0WU
LAMA-84	NWewXY5UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7vPZZKSzVyPUCuNFAxOTZ3IN88US=>	M1K1RXNCVkeHUh?=
CGTH-W-1	NV7XUWhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjRcHRKSzVyPUCuNFAyPjlizszN	MVrTRW5ITVJ?
KASUMI-1	NEXXbZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7rTWM2OD1yLkCwNlE4KM7:TR?=	MUnTRW5ITVJ?
BE-13	M1ftW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIO0Z4dKSzVyPUCuNFAzPTlizszN	NEm1OYVUSU6JRWK=
CTV-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTBwMEC1NlEh\|ryP	MUDTRW5ITVJ?
NKM-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml[xTWM2OD1yLkCwOlU2KM7:TR?=	MnGyV2FPT0WU
MONO-MAC-6	M3n3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3:zOWlEPTB;MD6wNFg{PyEQvF2=	NG\zclRUSU6JRWK=
A204	M2DzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwMEGyNVgh\|ryP	M4P5cXNCVkeHUh?=
GDM-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTBwMEG4N\|Mh\|ryP	Ml\aV2FPT0WU
AN3-CA	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmHzTWM2OD1yLkCxPFc{KM7:TR?=	NWn3Wm01W0GQR1XS
BL-70	NEnZcZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXxd\|Y4UUN3ME2wMlAzOTl7IN88US=>	NIfEVW5USU6JRWK=
Daudi	NXnuZ5pGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3SyVWlEPTB;MD6wNlU{PyEQvF2=	MYXTRW5ITVJ?
KU812	NXTVT3UxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;1UGlEPTB;MD6wNlg1QCEQvF2=	M{TienNCVkeHUh?=
KG-1	MoPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LUXmlEPTB;MD6wN\|I6PCEQvF2=	M1nlbXNCVkeHUh?=
DOHH-2	Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHMXYE4UUN3ME2wMlA1QDB\|IN88US=>	NVi2THVsW0GQR1XS
HuO9	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX64NW8zUUN3ME2wMlA2PDR6IN88US=>	Mme1V2FPT0WU
EB2	M3rSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7GR4Z5UUN3ME2wMlA2PTd4IN88US=>	MXrTRW5ITVJ?
G-402	M3W4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTBwME[zOFEh\|ryP	M37rUXNCVkeHUh?=
SU-DHL-1	MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwME[zO\|kh\|ryP	NHfCVW1USU6JRWK=
NCI-H719	M3HkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwMEe4PFgh\|ryP	M1TWPXNCVkeHUh?=
MLMA	MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjoXXQyUUN3ME2wMlA6ODZizszN	NU\xcmVjW0GQR1XS
KM12	NFrsXoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMEm3N\|ch\|ryP	NV\wSXZ3W0GQR1XS
SUP-T1	NU\GOGN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\ETWM2OD1yLkC5PVgzKM7:TR?=	NUTHN2g5W0GQR1XS
MZ1-PC	NYjFXmpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfTU5JKSzVyPUCuNVE{OzZizszN	M3:3THNCVkeHUh?=
MFE-296	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwMUG4N\|kh\|ryP	MkjtV2FPT0WU
ALL-PO	M4fuR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrPTWM2OD1yLkGyOFQ{KM7:TR?=	NFnRR\|RUSU6JRWK=
GB-1	MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwMUK1NVIh\|ryP	MkHzV2FPT0WU
SIG-M5	NVXiPYR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHOTWM2OD1yLkGzN\|ch\|ryP	M{HvfXNCVkeHUh?=
P30-OHK	NH35fYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlXETWM2OD1yLkG1OlczKM7:TR?=	MXLTRW5ITVJ?
NCI-H716	MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwMU[yOlYh\|ryP	MmHlV2FPT0WU
MPP-89	NWfOWFR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{K2VGlEPTB;MD6xOlk{OyEQvF2=	M2W3c3NCVkeHUh?=
SF126	M2m2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWe4ZmptUUN3ME2wMlE4ODZ\|IN88US=>	NGm4eXlUSU6JRWK=
CTB-1	M{DiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDae\|Z[UUN3ME2wMlE4OzF4IN88US=>	MWfTRW5ITVJ?
CA46	NVnLNpplT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwMUe0PFkh\|ryP	NH7zd4hUSU6JRWK=
NCI-H520	NViwXVdlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwMUe3N\|Ih\|ryP	NFP0[pVUSU6JRWK=
CAL-85-1	NVjuWW5ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFr6VoVKSzVyPUCuNVc6OjdizszN	NFrPRnZUSU6JRWK=
NCI-H2342	NFjTRYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVGxRnFqUUN3ME2wMlE5PTd5IN88US=>	MWnTRW5ITVJ?
697	Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;aZ4M3UUN3ME2wMlE5QDdzIN88US=>	NFvzXmRUSU6JRWK=
NY	NEXsOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTKR5VKSzVyPUCuNVkzQDdizszN	MoPrV2FPT0WU
T98G	NIDkNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfsPYk4UUN3ME2wMlE6OzF6IN88US=>	M1O0OHNCVkeHUh?=
NCI-H1703	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonMTWM2OD1yLkG5OlE2KM7:TR?=	Mo\kV2FPT0WU
NCI-H2087	M{jBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3i4TGlEPTB;MD6yNFQ{QSEQvF2=	M{LjSXNCVkeHUh?=
PF-382	M4D4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPhTWM2OD1yLkKwPFc{KM7:TR?=	Mmq2V2FPT0WU
HCT-116	M2jiZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXmw[FduUUN3ME2wMlIyODZ7IN88US=>	M3jOPHNCVkeHUh?=
CAKI-1	MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3n6UWlEPTB;MD6yNVY3PiEQvF2=	MXrTRW5ITVJ?
CCF-STTG1	NHPDRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnTUTWM2OD1yLkKyOFc2KM7:TR?=	M2T0NHNCVkeHUh?=
D-392MG	MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4Lte2lEPTB;MD6yN\|E4PyEQvF2=	MmrBV2FPT0WU
RT-112	M37r[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rXbmlEPTB;MD6yN\|c6PSEQvF2=	MVXTRW5ITVJ?
MES-SA	MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDVTWM2OD1yLkK0NVg4KM7:TR?=	M{\IZ3NCVkeHUh?=
LC-2-ad	NGfic5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofmTWM2OD1yLkK0NlY2KM7:TR?=	M1P0fnNCVkeHUh?=
NOS-1	M{\6dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3uNnVKSzVyPUCuNlQ{PjdizszN	NWHwZVRrW0GQR1XS
NALM-6	NEezRYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\ac2lEPTB;MD6yOVU1OyEQvF2=	M{W0XXNCVkeHUh?=
TE-15	Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPBTWM2OD1yLkK2NFkyKM7:TR?=	MXHTRW5ITVJ?
786-0	MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nxWWlEPTB;MD6yOlIzQCEQvF2=	NYDocWg4W0GQR1XS
IST-MES1	NFnJ[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\5TWM2OD1yLkK2PFI6KM7:TR?=	NXrG[Id4W0GQR1XS
KYSE-180	NFXQcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TDeWlEPTB;MD6yOlg6OSEQvF2=	MoLRV2FPT0WU
YT	M2TQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXmdGxSUUN3ME2wMlI3QTd2IN88US=>	Mo\VV2FPT0WU
A427	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mom0TWM2OD1yLkK3NlY1KM7:TR?=	NVfZTJFwW0GQR1XS
KYSE-450	NXfUS4dTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1e0eWlEPTB;MD6yO\|MzQSEQvF2=	MmjaV2FPT0WU
HuH-7	NITtOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTBwMke3OlMh\|ryP	MXrTRW5ITVJ?
CAS-1	M3rpcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoHjTWM2OD1yLkK4N\|A{KM7:TR?=	NWTJO5FkW0GQR1XS
KURAMOCHI	M4jrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\2[\|hKSzVyPUCuNlg1OTlizszN	MVfTRW5ITVJ?
ACHN	Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXrTWM2OD1yLkK5N\|I{KM7:TR?=	NXj5fVZ6W0GQR1XS
HGC-27	NWDZWpl5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVS0VGhSUUN3ME2wMlI6OzV\|IN88US=>	M2LR[nNCVkeHUh?=
A172	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfyTWM2OD1yLkK5OVc4KM7:TR?=	M2rpcHNCVkeHUh?=
SNU-449	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHSwcYZKSzVyPUCuNlk6PjRizszN	MnLxV2FPT0WU
SW982	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHVTWM2OD1yLkK5PVc5KM7:TR?=	MXfTRW5ITVJ?
EFO-21	MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTBwM{C0NVEh\|ryP	MYDTRW5ITVJ?
NCI-H2030	MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkOzTWM2OD1yLkOxNVY1KM7:TR?=	M3PyXHNCVkeHUh?=
HT-144	NVL0W3RVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnJPIxDUUN3ME2wMlMyOjhizszN	NIPsOYFUSU6JRWK=
MFE-280	NXP6NnBFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvBTWM2OD1yLkOxOFU{KM7:TR?=	NILtcJFUSU6JRWK=
SK-LU-1	NHLhWYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfkS3BUUUN3ME2wMlMyPDZ4IN88US=>	NULDd4ZUW0GQR1XS
NCI-H2052	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XG[WlEPTB;MD6zNVQ5PCEQvF2=	MkT5V2FPT0WU
SK-HEP-1	MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjETWM2OD1yLkOzN\|Y5KM7:TR?=	MXzTRW5ITVJ?
QIMR-WIL	M4r5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjWNFhKSzVyPUCuN\|M1OjRizszN	NUfFU4VjW0GQR1XS
A2780	Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\HTWM2OD1yLkO0N\|A1KM7:TR?=	MlzhV2FPT0WU
ACN	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XuUGlEPTB;MD6zOFg4OyEQvF2=	NXm5W2NGW0GQR1XS
BxPC-3	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwM{S5PFkh\|ryP	NX3R[2RNW0GQR1XS
BCPAP	M2TNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7PRYVKSzVyPUCuN\|YxODFizszN	M1;2b3NCVkeHUh?=
HOP-62	MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWTveWpkUUN3ME2wMlM3OTB4IN88US=>	Mn[xV2FPT0WU
SW1710	NIrnN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HPcWlEPTB;MD6zOlQ2PSEQvF2=	NHjBfHFUSU6JRWK=
OPM-2	MlywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwM{[0O\|Mh\|ryP	NITO[FBUSU6JRWK=
DBTRG-05MG	MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnJSoRKSzVyPUCuN\|gxPTRizszN	MVLTRW5ITVJ?
SK-MEL-24	M3\pZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zNN2lEPTB;MD6zPVc6OSEQvF2=	MoDEV2FPT0WU
8305C	MmfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPwTWM2OD1yLkO5O\|k{KM7:TR?=	NG[5eXVUSU6JRWK=
OVCAR-4	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjzSYpKSzVyPUCuOFE2QDZizszN	NETGRXNUSU6JRWK=
HLE	NFPoXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnxeFVKSzVyPUCuOFE5PiEQvF2=	MnqyV2FPT0WU
NCI-H747	NHz0VoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1XsNWlEPTB;MD60NlE{PyEQvF2=	MYLTRW5ITVJ?
SW780	NEjLTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrBb3ZyUUN3ME2wMlQzOzR4IN88US=>	NWHpPFd5W0GQR1XS
KYSE-150	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37pcmlEPTB;MD60NlQyPSEQvF2=	NX;HcFF4W0GQR1XS
H4	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TxeGlEPTB;MD60NlQ2OSEQvF2=	MWLTRW5ITVJ?
SW1088	M2jNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwNESzPUDPxE1?	M3nxfXNCVkeHUh?=
SF268	NFrUVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTvbotJUUN3ME2wMlQ1QDZizszN	MXPTRW5ITVJ?
RT4	NXfWVG1TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzlT5BKSzVyPUCuOFUyOTFizszN	NVzqWoIxW0GQR1XS
NCI-H522	NX7qTnFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHX1e45KSzVyPUCuOFUzPyEQvF2=	NGq0WoxUSU6JRWK=
LCLC-97TM1	NIjSfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnMRYsyUUN3ME2wMlQ3OTl3IN88US=>	MVjTRW5ITVJ?
CAL-39	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\SZmlEPTB;MD60OlUyQSEQvF2=	MXTTRW5ITVJ?
CAL-120	M4nzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TpZmlEPTB;MD60O\|Y1OyEQvF2=	NEPrTG9USU6JRWK=
ESS-1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwNEe4NlEh\|ryP	Mnz4V2FPT0WU
KARPAS-45	M17rSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzlbYJvUUN3ME2wMlQ5QTN\|IN88US=>	NXjWXXB[W0GQR1XS
DU-4475	M4nGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3H4ZmlEPTB;MD60PVUyOSEQvF2=	NIiyZnRUSU6JRWK=
VMRC-RCZ	NVG2Xo5{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTBwNEm5NFQh\|ryP	M2nUVXNCVkeHUh?=
HOS	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jaRWlEPTB;MD61NFM3PSEQvF2=	NUnheXBnW0GQR1XS
MOLT-16	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zmTWlEPTB;MD61NVgxQCEQvF2=	MVfTRW5ITVJ?
RPMI-6666	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwNUKxN\|Uh\|ryP	NEHRdWZUSU6JRWK=
K052	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLrc4N3UUN3ME2wMlUzOTRizszN	MkfsV2FPT0WU
EHEB	NFj5S21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkL6TWM2OD1yLkWyNVgzKM7:TR?=	NGe0cohUSU6JRWK=
MFH-ino	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwNUKzOVEh\|ryP	MYLTRW5ITVJ?
A4-Fuk	M4fR[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLmWnh2UUN3ME2wMlUzPTJ6IN88US=>	NFHqeJVUSU6JRWK=
SW1417	Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTOSI9PUUN3ME2wMlUzPzhzIN88US=>	MnjTV2FPT0WU
DoTc2-4510	NUK5[4NQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLHTWM2OD1yLkW0PVU5KM7:TR?=	M{fBd3NCVkeHUh?=
TE-12	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTBwNUW3N\|Uh\|ryP	NYnReWxKW0GQR1XS
8-MG-BA	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1yxb2lEPTB;MD61OlA2PiEQvF2=	NEXaWHFUSU6JRWK=
ECC12	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwNU[1OVgh\|ryP	MYXTRW5ITVJ?
CHL-1	NX[zdIRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHWzSGNKSzVyPUCuOVc1PjNizszN	NH3nSIJUSU6JRWK=
LCLC-103H	NXnYUFhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DZNGlEPTB;MD61PFM1PCEQvF2=	NHvFNYZUSU6JRWK=
OS-RC-2	NEPVTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MULJR\|UxRTBwNUizO\|kh\|ryP	NFX6SnhUSU6JRWK=
RO82-W-1	M1;YeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXUZW1KSzVyPUCuOVk3OTVizszN	M4PzTnNCVkeHUh?=
A3-KAW	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHvTnBKSzVyPUCuOlE1PjdizszN	NE\SdHVUSU6JRWK=
NCCIT	MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwNkG3NVUh\|ryP	M3\aeHNCVkeHUh?=
IST-SL2	NW\wS2Q2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7C[o5sUUN3ME2wMlYzPTJ{IN88US=>	NYWzbmZnW0GQR1XS
GI-ME-N	MkDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\odIZKSzVyPUCuOlMxPjlizszN	NXvNco02W0GQR1XS
ES6	NGnYZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nDUmlEPTB;MD62N\|I6PSEQvF2=	MVLTRW5ITVJ?
BL-41	NHvDPXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHq5O2NKSzVyPUCuOlM{PTJizszN	NYDmbFZzW0GQR1XS
Ca-Ski	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXIUYJwUUN3ME2wMlY1QDFizszN	MXPTRW5ITVJ?
HOP-92	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwNkW2O\|Ih\|ryP	M3fZ[3NCVkeHUh?=
SK-LMS-1	M1jGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDmR3d3UUN3ME2wMlY3PDdizszN	MmPMV2FPT0WU
EW-13	NF[5bpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwNk[3O\|kh\|ryP	NFniRZJUSU6JRWK=
647-V	MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkTRTWM2OD1yLk[4NVQ5KM7:TR?=	M{nOR3NCVkeHUh?=
JiyoyeP-2003	NGryV2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjtSJhKSzVyPUCuOlk4OzhizszN	M{e0dHNCVkeHUh?=
WSU-NHL	NEH3e3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{joZWlEPTB;MD63NFg5PyEQvF2=	NGHHcpJUSU6JRWK=
U-698-M	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvDOopEUUN3ME2wMlcyODZ\|IN88US=>	M1;JdnNCVkeHUh?=
HC-1	NUTLXZJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTBwN{K0NFUh\|ryP	NUjLTlhHW0GQR1XS
8505C	NGD1d2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwN{K3OFEh\|ryP	NV3UVVJoW0GQR1XS
HUTU-80	NUDrS3RFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLDUHlMUUN3ME2wMlc{OzR7IN88US=>	NGrs[pVUSU6JRWK=
LB1047-RCC	NXKyOGxjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXT6O2V7UUN3ME2wMlc{PTN6IN88US=>	NUfkNJF3W0GQR1XS
GAMG	M4nlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3n0PGlEPTB;MD63N\|Y2OyEQvF2=	MmnRV2FPT0WU
CAL-12T	M3myfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUmxTVBjUUN3ME2wMlc{QDd5IN88US=>	NWDXOIw3W0GQR1XS
NCI-SNU-1	NVi1O4RsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIH2eWZKSzVyPUCuO\|czPzhizszN	NV3ac5BoW0GQR1XS
HTC-C3	MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LkXWlEPTB;MD63O\|Q2OSEQvF2=	NIjjdnRUSU6JRWK=
HPAF-II	MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHrTWM2OD1yLke3OVAyKM7:TR?=	MkPNV2FPT0WU
KGN	NELk[ZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFOxb5FKSzVyPUCuO\|gxQDFizszN	NHXRd\|ZUSU6JRWK=
EFO-27	M4XvZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDYWFdKSzVyPUCuO\|g4OzNizszN	Mof0V2FPT0WU
MEL-HO	M3;0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrJXnoxUUN3ME2wMlc6PDR7IN88US=>	M4jRdnNCVkeHUh?=
KYSE-270	NVTaenJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nMfWlEPTB;MD64NFUzQSEQvF2=	NIXKPG1USU6JRWK=
NCI-H1755	NILRTpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTBwOEC3NVQh\|ryP	MUXTRW5ITVJ?
MFM-223	NUXjVYhvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2XVZWlEPTB;MD64NVQxPyEQvF2=	MXjTRW5ITVJ?
G-361	NF\FfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHzFVHJKSzVyPUCuPFE5QTdizszN	NXzlT5BlW0GQR1XS
ETK-1	NV3heYtnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVz5[lB5UUN3ME2wMlgzPDRzIN88US=>	M{KwfnNCVkeHUh?=
LU-99A	MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jZOWlEPTB;MD64OFcxOSEQvF2=	NY[5[nlqW0GQR1XS
IST-MEL1	MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MorzTWM2OD1yLki1O\|MzKM7:TR?=	NIOxfIVUSU6JRWK=
L-540	NVu2fHlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTBwOEW4NFEh\|ryP	M2PqNXNCVkeHUh?=
U-2-OS	NEO0VY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm[zTWM2OD1yLki1PFQ3KM7:TR?=	M1LtenNCVkeHUh?=
HT-1376	NF[zSZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjzTWdKSzVyPUCuPFYxPTFizszN	NEHkdYNUSU6JRWK=
COLO-680N	MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFSyVndKSzVyPUCuPFc6OzNizszN	MnLUV2FPT0WU
NCI-H1581	MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwOEmyPVch\|ryP	M37nOHNCVkeHUh?=
HuCCT1	MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLITWM2OD1yLki5OVQ5KM7:TR?=	M{DHW3NCVkeHUh?=
BB30-HNC	MmniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLJTWM2OD1yLkmyOFY6KM7:TR?=	M4XZVHNCVkeHUh?=
NCI-H2347	M33Bfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{i3[GlEPTB;MD65N\|I6OiEQvF2=	MkHVV2FPT0WU
G-401	NYTlUpd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Syc2lEPTB;MD65N\|Y6PSEQvF2=	M2PVNHNCVkeHUh?=
NCI-H358	M{jQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRTBwOUWwNVQh\|ryP	MYPTRW5ITVJ?
HCC1395	MknzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjRdWliUUN3ME2wMlk2PDZzIN88US=>	M1\2WnNCVkeHUh?=
J82	Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3G1N2lEPTB;MD65OVU1OyEQvF2=	NELiN4hUSU6JRWK=
KE-37	MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjHTWM2OD1yLkm2N\|g4KM7:TR?=	MVnTRW5ITVJ?
NOMO-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnYTWM2OD1yLkm2OVY1KM7:TR?=	M{TGcHNCVkeHUh?=
ML-2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHLbHpKSzVyPUCuPVk4PSEQvF2=	MX3TRW5ITVJ?
SW872	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXiW2tKSzVyPUCuPVk4PzVizszN	MWPTRW5ITVJ?
KYSE-520	NIHBTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfFTWM2OD1zLkCwOFk1KM7:TR?=	NVy5eGMzW0GQR1XS
HL-60	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXsTWM2OD1zLkCwPVch\|ryP	M4rNfHNCVkeHUh?=
HDLM-2	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7kTWM2OD1zLkCxNlUzKM7:TR?=	M1HZWXNCVkeHUh?=
MIA-PaCa-2	NX3ORpBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPPWmFKSzVyPUGuNFE{PzVizszN	MUXTRW5ITVJ?
TCCSUP	M{TER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHi3cI9KSzVyPUGuNFE4OzJizszN	M3;o[nNCVkeHUh?=
SH-4	NGWyN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLxR2NlUUN3ME2xMlAzOjR2IN88US=>	NGjYfVVUSU6JRWK=
MG-63	M2\odGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\EZmlEPTB;MT6wNlYyPiEQvF2=	MY\TRW5ITVJ?
NB6	Mnr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEi4VGJKSzVyPUGuNFMyODlizszN	MX;TRW5ITVJ?
CAL-54	M4qye2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4Lic2lEPTB;MT6wN\|k2QSEQvF2=	M2TFZXNCVkeHUh?=
DU-145	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTFwMEiwO\|Mh\|ryP	NFrKR4lUSU6JRWK=
HCE-4	M3TBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFna[JdKSzVyPUGuNFkzQDZizszN	M1PuUXNCVkeHUh?=
U-266	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU[yXIxEUUN3ME2xMlA6PjN\|IN88US=>	MXPTRW5ITVJ?
HT-1197	NH6y[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3TZVJpUUN3ME2xMlEyPDN6IN88US=>	MoDaV2FPT0WU
EW-1	MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkXZTWM2OD1zLkG0NVI5KM7:TR?=	MYHTRW5ITVJ?
MHH-NB-11	NUXXWYFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmq2TWM2OD1zLkG1N\|Y5KM7:TR?=	MUjTRW5ITVJ?
NCI-H2405	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37FfGlEPTB;MT6xOlE3KM7:TR?=	NX\sfYQ6W0GQR1XS
COLO-668	MlzTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEG4PIdKSzVyPUGuNVY1QSEQvF2=	NGPWWG1USU6JRWK=
IMR-5	M3P5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfuO\|hUUUN3ME2xMlE3QTN4IN88US=>	Mo\BV2FPT0WU
ARH-77	NEDjZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn;BTWM2OD1zLkKyPVI1KM7:TR?=	MV\TRW5ITVJ?
BHT-101	NIq5Z5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYq0U2dmUUN3ME2xMlI{PDlizszN	MVXTRW5ITVJ?
SCC-25	NWTsdWQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXPTWM2OD1zLkKzOVM3KM7:TR?=	MlzRV2FPT0WU
NTERA-S-cl-D1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\qTWM2OD1zLkK0N\|Q3KM7:TR?=	MVrTRW5ITVJ?
MKN28	NGH4TnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmn4TWM2OD1zLkK1OlM3KM7:TR?=	MWnTRW5ITVJ?
KS-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvnR\|dbUUN3ME2xMlI5OjZ7IN88US=>	NIq0d4NUSU6JRWK=
NCI-H1734	NUHuU2YzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfzTW9KSzVyPUGuNlg6OTNizszN	MULTRW5ITVJ?
ES7	NI\LXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTFwMkm1OFIh\|ryP	MUXTRW5ITVJ?
NCI-H838	MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fVe2lEPTB;MT6zNFYyPSEQvF2=	M3[wbnNCVkeHUh?=
HEC-1	NH3lXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTDR5ExUUN3ME2xMlM{PzV3IN88US=>	NFjG[2dUSU6JRWK=
ME-180	NUjVT45iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\MXWlEPTB;MT6zO\|k6OyEQvF2=	NI\N[nhUSU6JRWK=
MMAC-SF	NH7TOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fWWWlEPTB;MT6zPVU6PSEQvF2=	MYPTRW5ITVJ?
IA-LM	NUTFcZliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\iToZKSzVyPUGuOFA6OTRizszN	NH\Z[olUSU6JRWK=
MN-60	NYS0XGtDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3z5SGlEPTB;MT60N\|EyPCEQvF2=	MV7TRW5ITVJ?
SIMA	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIPkSnlKSzVyPUGuOFg3QDdizszN	NFHMbGZUSU6JRWK=
NCI-H1770	NWDU[FdXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVGzXIw{UUN3ME2xMlUzODV2IN88US=>	NX;wUFVXW0GQR1XS
ONS-76	NE\oO3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnUR3NKSzVyPUGuOVI{OTFizszN	NWm1Z4p6W0GQR1XS
LB771-HNC	Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUL1[ploUUN3ME2xMlU{QTB4IN88US=>	MnzXV2FPT0WU
SW48	M2XXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\vTWM2OD1zLkW0NlQ{KM7:TR?=	M{PmWnNCVkeHUh?=
KYSE-140	NGr3WplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\TeWZwUUN3ME2xMlU2PzRzIN88US=>	M2[wPXNCVkeHUh?=
SW626	NWjvSmdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTFwNUixOkDPxE1?	NX\3VYhrW0GQR1XS
MC-CAR	MmXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rvNGlEPTB;MT61PFY3OyEQvF2=	MWHTRW5ITVJ?
D-336MG	NF;xS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkT1TWM2OD1zLk[yPVQh\|ryP	NUfkVZF2W0GQR1XS
SK-MEL-3	NYjxRllXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXyyV29yUUN3ME2xMlY{QTB{IN88US=>	Mn;wV2FPT0WU
MHH-PREB-1	Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrGTWM2OD1zLk[0OFc{KM7:TR?=	M3iySHNCVkeHUh?=
Calu-1	M{HGVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPPTWM2OD1zLk[1N\|g3KM7:TR?=	M{Lid3NCVkeHUh?=
HCC1806	M3TodWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTFwNk[2NVEh\|ryP	NGraXnBUSU6JRWK=
A101D	MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DRbGlEPTB;MT62Olc5OSEQvF2=	MUjTRW5ITVJ?
A704	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofzTWM2OD1zLk[4N\|EyKM7:TR?=	NUnJOlI5W0GQR1XS
LB831-BLC	MknVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTFwNkm4OVQh\|ryP	Mlm2V2FPT0WU
RL95-2	NETwcHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPUTWM2OD1zLkexOFY{KM7:TR?=	MULTRW5ITVJ?
RPMI-2650	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTFwN{K3NVkh\|ryP	MUPTRW5ITVJ?
NH-12	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnu2TWM2OD1zLkezOFI4KM7:TR?=	NXTrWIFDW0GQR1XS
AGS	NEf3OlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHsNIVKSzVyPUGuO\|Y{PThizszN	MonYV2FPT0WU
NEC8	MlnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFn0T2hKSzVyPUGuO\|g6QTVizszN	NWPJS241W0GQR1XS
NCI-H2009	MoP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\wdlZKSzVyPUGuO\|k4OjFizszN	MU\TRW5ITVJ?
A498	NELlRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVT4RlNzUUN3ME2xMlgyOjh{IN88US=>	MYjTRW5ITVJ?
NCI-H810	NW\qV4dWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3iTWM2OD1zLkixOlA3KM7:TR?=	NWCw[I5IW0GQR1XS
SK-NEP-1	NFXmcJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRTFwOEO3Olch\|ryP	NHfNUGdUSU6JRWK=
D-542MG	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTFwOEW4OVEh\|ryP	NXLGXXNbW0GQR1XS
KNS-42	NWjGXYptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnq2TWM2OD1zLki2NlY3KM7:TR?=	MXTTRW5ITVJ?
NCI-H2452	MlHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDQNVNKSzVyPUGuPFkxPzRizszN	NVP5c2RvW0GQR1XS
SK-MEL-2	NILLcFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LIdmlEPTB;MT65NFI4OSEQvF2=	NGnUU21USU6JRWK=
OVCAR-5	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnibndiUUN3ME2xMlkxPjd3IN88US=>	NUe1cFZXW0GQR1XS
SNG-M	M4rR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\t[2lEPTB;MT65OVg2QCEQvF2=	NVr3c5U{W0GQR1XS
A673	M2T6O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPTTWM2OD1zLkm3OVE3KM7:TR?=	MWfTRW5ITVJ?
L-428	MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjQc3hvUUN3ME2xMlk6OTd7IN88US=>	MorkV2FPT0WU
KM-H2	M1LNTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\sRmlEPTB;Mj6wNVA6KM7:TR?=	NVLS[GZVW0GQR1XS
MC-IXC	NFHu[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7aTXFKSzVyPUKuNFIzPzNizszN	NFLZUFdUSU6JRWK=
COLO-678	NUDaXpVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTJwMESyNFch\|ryP	NILQVGNUSU6JRWK=
MEL-JUSO	M1\vS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHtdINpUUN3ME2yMlA4QDVzIN88US=>	MlPmV2FPT0WU
HCC38	MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{i1ZmlEPTB;Mj6wPFQ{OyEQvF2=	MV;TRW5ITVJ?
UACC-62	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TuR2lEPTB;Mj6wPFg2PSEQvF2=	NH;Tb4dUSU6JRWK=
OAW-42	NYXHXmhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTJwMEm3NVEh\|ryP	MXLTRW5ITVJ?
LB996-RCC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWWweHVuUUN3ME2yMlE{QDF5IN88US=>	MlPBV2FPT0WU
COR-L105	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTJwMU[zO\|Mh\|ryP	M{XVOnNCVkeHUh?=
RCC10RGB	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3pTWM2OD1{LkG4OVc3KM7:TR?=	MYfTRW5ITVJ?
A431	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fEfWlEPTB;Mj6xPVAyQSEQvF2=	NYPuOGNzW0GQR1XS
NCI-H292	NIfTZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DKfmlEPTB;Mj6yN\|k2OSEQvF2=	MmTHV2FPT0WU
SK-UT-1	NV\Se41[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LTemlEPTB;Mj6zN\|E5PCEQvF2=	MmixV2FPT0WU
PANC-08-13	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYW2Nm9jUUN3ME2yMlM{OjN3IN88US=>	NHPTTnFUSU6JRWK=
ST486	M3TQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;LXmlEPTB;Mj60NVA1QCEQvF2=	M33tOHNCVkeHUh?=
SJSA-1	NXThVJprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlu3TWM2OD1{LkSxNlcyKM7:TR?=	Mn;qV2FPT0WU
RKO	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLxTWM2OD1{LkSyNFI6KM7:TR?=	MlHTV2FPT0WU
NCI-H1793	MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TXbWlEPTB;Mj60OFAzQSEQvF2=	NV3RUnZRW0GQR1XS
639-V	M3\OUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHzTWM2OD1{LkS1N\|gzKM7:TR?=	MV3TRW5ITVJ?
ES3	NHTVOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PoXWlEPTB;Mj60PVc{PyEQvF2=	M3LZenNCVkeHUh?=
NCI-H1792	Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjL[Y5KSzVyPUKuOVY5OjZizszN	NUTDPIFrW0GQR1XS
NCI-H1651	M3TaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\YUWpKSzVyPUKuOVgzOSEQvF2=	NV60[YNlW0GQR1XS
SN12C	NIjNd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUOxPWluUUN3ME2yMlU5PDh5IN88US=>	NWO5SHkyW0GQR1XS
COLO-679	NW\wNIVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3:yWmlEPTB;Mj61PFYxPSEQvF2=	NYWxRYVvW0GQR1XS
U-118-MG	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjQTWM2OD1{LkW4PFczKM7:TR?=	M{XudnNCVkeHUh?=
Ramos-2G6-4C10	M1Gwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTJwNkS4NFch\|ryP	MoH1V2FPT0WU
HCT-15	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrMWINKSzVyPUKuOlg4QTJizszN	NV7FPI5KW0GQR1XS
MDA-MB-157	NFfwfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3wTWM2OD1{LkewO\|Q4KM7:TR?=	MnXWV2FPT0WU
K5	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofUTWM2OD1{LkexPFQ2KM7:TR?=	NU\mTJBmW0GQR1XS
MKN45	M{e4Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jmSGlEPTB;Mj63N\|M3PiEQvF2=	MlzNV2FPT0WU
DMS-273	Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13LcWlEPTB;Mj63OVY{OiEQvF2=	Mmj2V2FPT0WU
C8166	NEXvfVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTJwN{i1NVMh\|ryP	MoHyV2FPT0WU
Calu-3	M2POTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjsXXIyUUN3ME2yMlc5QTZ7IN88US=>	NF\NT\|JUSU6JRWK=
SNB75	NUK5WVYyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnjb2JKSzVyPUKuPFg2OzVizszN	MYrTRW5ITVJ?
BFTC-905	MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHv4dplKSzVyPUKuPVAyQTFizszN	M3TxOHNCVkeHUh?=
C-4-II	NVnseY1MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLQ[5ltUUN3ME2yMlkyOzV\|IN88US=>	Mmf1V2FPT0WU
MS-1	M1rndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTJwOU[3Olkh\|ryP	M{HDe3NCVkeHUh?=
A375	NETDTVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHHqeGRKSzVyPUOuNFgyQDRizszN	MWXTRW5ITVJ?
KYSE-70	NH:3[4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTNwMEi4PFIh\|ryP	NVvwTI0{W0GQR1XS
KYSE-510	NGnGc\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTNwMUC5PVUh\|ryP	M2C1N3NCVkeHUh?=
LN-405	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHiTodmUUN3ME2zMlE{PTF6IN88US=>	Mnj4V2FPT0WU
BOKU	NHLkbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPnTWM2OD1\|LkG0NlU3KM7:TR?=	MnfqV2FPT0WU
TE-10	NGi0c\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml25TWM2OD1\|LkG3N\|YzKM7:TR?=	NXLoPZNnW0GQR1XS
MKN1	MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVO4WXpZUUN3ME2zMlE5PDh\|IN88US=>	NHPabnhUSU6JRWK=
M059J	Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY\JR\|UxRTNwMkCxO\|Mh\|ryP	NIm0[W9USU6JRWK=
GOTO	NIHwcIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTNwMkKwN\|kh\|ryP	MYfTRW5ITVJ?
DK-MG	MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTNwMkW5O\|Yh\|ryP	NEfHd4xUSU6JRWK=
NCI-H727	NHfh[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml74TWM2OD1\|LkK2OVgh\|ryP	Ml;sV2FPT0WU
NB12	M36ycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7DV29{UUN3ME2zMlM{OjJ2IN88US=>	MkLNV2FPT0WU
DOK	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTNwM{[xPFYh\|ryP	MnH2V2FPT0WU
KYSE-410	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjocIMxUUN3ME2zMlM3Ojh5IN88US=>	MVHTRW5ITVJ?
AM-38	NH\NUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrH[FZ4UUN3ME2zMlM5ODVzIN88US=>	M{XPTXNCVkeHUh?=
GR-ST	M2XzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPWeJJKSzVyPUOuOFU4OzJizszN	NWm1RodIW0GQR1XS
D-247MG	M3vPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTNwNEiyOlMh\|ryP	MoWxV2FPT0WU
TE-8	NYf3eIwyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTNwNEmzN\|Mh\|ryP	MkflV2FPT0WU
LS-411N	NGDYd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnId5dKSzVyPUOuOFk3QTJizszN	MnTIV2FPT0WU
SK-MES-1	NIj3UHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPHTWM2OD1\|LkW2OFM{KM7:TR?=	NUj0fpVYW0GQR1XS
SF295	MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmL4TWM2OD1\|Lk[xOVUzKM7:TR?=	MnzyV2FPT0WU
SK-MEL-30	NV\EXolGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYrJR\|UxRTNwNkW5NlEh\|ryP	NIPhT4pUSU6JRWK=
LB2241-RCC	NFzBfXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnyPGdWUUN3ME2zMlY3OjZizszN	M4\CO3NCVkeHUh?=
PC-14	MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXizOpVxUUN3ME2zMlY3PDN5IN88US=>	MoCxV2FPT0WU
EW-7	MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTNwNke2PVMh\|ryP	NYDKSXNUW0GQR1XS
NMC-G1	M1jld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUj4Z3hjUUN3ME2zMlcyQDN5IN88US=>	NYHDUnpUW0GQR1XS
TE-441-T	M1Tj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33HcWlEPTB;Mz63N\|AzQCEQvF2=	NIn6dmJUSU6JRWK=
NCI-H1618	M2XRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXVSItjUUN3ME2zMlgyQDd3IN88US=>	NUTTSHhTW0GQR1XS
PANC-03-27	MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTNwOEG5NVYh\|ryP	MnzSV2FPT0WU
NCI-H2228	NIXsVmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\T[mlEPTB;Mz64N\|EzPiEQvF2=	NGfwdpNUSU6JRWK=
CAPAN-1	M{DY[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXHN\|FKSzVyPUOuPFcxODlizszN	NIXzOmRUSU6JRWK=
KLE	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLmTWM2OD1\|LkmwOlch\|ryP	NF\RSIdUSU6JRWK=
Becker	MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzY[41KSzVyPUOuPVI5PDlizszN	MnH3V2FPT0WU
SK-PN-DW	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTRwMEe5O\|Qh\|ryP	NVPY[XJnW0GQR1XS
Hs-578-T	M1rwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rtNGlEPTB;ND6wPFMxPiEQvF2=	MXfTRW5ITVJ?
RS4-11	MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fwWWlEPTB;ND6xNVI2PSEQvF2=	M2DJUHNCVkeHUh?=
D-502MG	M{PWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1nRemlEPTB;ND6xOlk6PyEQvF2=	MYnTRW5ITVJ?
GI-1	NF7zdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTRwMkiyPVkh\|ryP	MmHmV2FPT0WU
NCI-H209	NHPIUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXL3TmdPUUN3ME20MlM{PzhizszN	MYnTRW5ITVJ?
SK-OV-3	MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTkUWM{UUN3ME20MlQ5OTR7IN88US=>	NE\XfI9USU6JRWK=
LOUCY	NIC1OYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTRwNEi0N\|Ih\|ryP	M{i5T3NCVkeHUh?=
NCI-H69	NVfGWIxYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlH0TWM2OD12LkWxO\|k{KM7:TR?=	M{nwUnNCVkeHUh?=
SCC-9	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEf5bXVKSzVyPUSuOVMyPzJizszN	MoLPV2FPT0WU
NCI-H526	NEDKNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTRwNUmyPVMh\|ryP	M1rxb3NCVkeHUh?=
NCI-H2170	NV33VHI6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXI[\|NKSzVyPUSuOlY4PzFizszN	NVzzUXFZW0GQR1XS
SR	NFHKRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HSUmlEPTB;ND63NFA1QCEQvF2=	MmPXV2FPT0WU
CMK	M1PydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPSTWM2OD12LkeyNVAyKM7:TR?=	M3fvNHNCVkeHUh?=
COLO-829	NYPjW3BFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVmyNWZpUUN3ME20Mlc4ODR\|IN88US=>	NUnIOZN[W0GQR1XS
HuO-3N1	M2n1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTRwOEOyPFEh\|ryP	NILacnNUSU6JRWK=
5637	M{Cwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGWySZFKSzVyPUSuPVA1QDdizszN	MlfOV2FPT0WU
A253	M2jmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LzV2lEPTB;ND65O\|cxQCEQvF2=	NYLRfnNWW0GQR1XS
NB10	MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HKfGlEPTB;NT6wO\|Q6PyEQvF2=	MkHZV2FPT0WU
SF539	NVznd5FFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjsbYpKSzVyPUWuNFk6PTlizszN	M2SwN3NCVkeHUh?=
HAL-01	NIHxU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXkTWM2OD13LkG0OlQ2KM7:TR?=	Mk\pV2FPT0WU
MHH-ES-1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HMRWlEPTB;NT6xOlkzPSEQvF2=	NGfzWlBUSU6JRWK=
DEL	NHLE[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlS4TWM2OD13LkK3OVgzKM7:TR?=	NGfk[m1USU6JRWK=
NCI-H1299	NYrCZ25ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTVwM{WwNFch\|ryP	NXPxUXN5W0GQR1XS
ChaGo-K-1	M4Ox[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3UT2xKSzVyPUWuN\|UyODdizszN	NVvFUINTW0GQR1XS
HMV-II	NX;E[4JWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXTSXoYzUUN3ME21MlM6PDNizszN	MVrTRW5ITVJ?
NB69	NYS2TmUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnmzTWM2OD13LkO5OlMyKM7:TR?=	NFXTOFdUSU6JRWK=
NCI-H1882	MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPJTWM2OD13LkSzN\|Y1KM7:TR?=	M1nYenNCVkeHUh?=
SNU-475	M3G4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrpenVKSzVyPUWuOFcyPzFizszN	M1XEbHNCVkeHUh?=
RXF393	M1;GWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIq5cFZKSzVyPUWuOFg1QTRizszN	NEDT[nJUSU6JRWK=
CAL-51	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4rLXWlEPTB;NT62Nlg2OyEQvF2=	NHzKSZJUSU6JRWK=
SW1573	NYK3TW4xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TFbWlEPTB;NT62N\|U{PCEQvF2=	NELsV4ZUSU6JRWK=
GCT	Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M335R2lEPTB;NT63OVkzQSEQvF2=	NFHBbIJUSU6JRWK=
COR-L88	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGj5T2tKSzVyPUWuO\|Y5PDZizszN	NF\6UW5USU6JRWK=
MDA-MB-134-VI	MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\2cmR1UUN3ME21Mlg4PTN4IN88US=>	MmfVV2FPT0WU
NB5	NWC4[pptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzuTWM2OD13LkmyOFQh\|ryP	NIXoUJJUSU6JRWK=
GMS-10	MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;sS3JnUUN3ME21Mlk3QDZzIN88US=>	MmOyV2FPT0WU
CHP-212	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkKxTWM2OD14LkS4NlY4KM7:TR?=	NIHPSppUSU6JRWK=
TE-11	NVTMOHR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DZRmlEPTB;Nj61OVE5OiEQvF2=	NF70VZNUSU6JRWK=
SW962	MojQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zGU2lEPTB;Nj62OVc4PCEQvF2=	MV\TRW5ITVJ?
MZ2-MEL	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGC0cnJKSzVyPU[uPFIxOTFizszN	MUTTRW5ITVJ?
C-33-A	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW\h[nY3UUN3ME22MlkyPjh6IN88US=>	NUjGTWx6W0GQR1XS
IGR-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULifWhVUUN3ME22Mlk4QDJ4IN88US=>	M1TUenNCVkeHUh?=
MOLT-4	NVeyRW12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTdwMUW0NFYh\|ryP	MWLTRW5ITVJ?
NCI-H1650	M4LPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTdwMkewOFYh\|ryP	NVPGeJRHW0GQR1XS
AsPC-1	NWPMS\|BVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlntTWM2OD15LkK4OlA2KM7:TR?=	MWXTRW5ITVJ?
SNU-C2B	NWHkR4Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPXTWM2OD15LkK5OVcyKM7:TR?=	MkPiV2FPT0WU
MKN7	NITZdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHUPI1KSzVyPUeuN\|czOzVizszN	NGXGXmVUSU6JRWK=
SW620	NF24[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTdwM{iyNFUh\|ryP	M3Trc3NCVkeHUh?=
SK-MEL-28	NHHwZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\2R3pnUUN3ME23MlQxPzl6IN88US=>	NVywWoR2W0GQR1XS
TE-6	NWnOdoh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;XRmlEPTB;Nz60OFkxQCEQvF2=	M3f5T3NCVkeHUh?=
D-263MG	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF;ZSlJKSzVyPUeuOFU4PjJizszN	NULSNZdqW0GQR1XS
NCI-H1355	NInTfmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvrTWM2OD15Lke3NFI6KM7:TR?=	NX;OSG1IW0GQR1XS
DSH1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRTdwN{m3OlIh\|ryP	NWr3Z3k3W0GQR1XS
NCI-H460	NVrSb2ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlOxTWM2OD16LkCwOlk1KM7:TR?=	NXzwUGNPW0GQR1XS
NCI-H1563	NXK2bo9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDZTWM2OD16LkC3OVA5KM7:TR?=	NE\BWWFUSU6JRWK=
SW948	M{TTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3TDbGlEPTB;OD6xNFc1PCEQvF2=	NW\wNXdxW0GQR1XS
LK-2	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDCTWM2OD16LkGyPFM{KM7:TR?=	M3T5bXNCVkeHUh?=
HT-1080	M4DuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRThwMUOxO\|Uh\|ryP	M2C5fHNCVkeHUh?=
NCI-H441	MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIL2WW1KSzVyPUiuNVk{KM7:TR?=	NX;JeVduW0GQR1XS
HSC-4	NIP0WXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRThwMki3NkDPxE1?	NVPGNo0xW0GQR1XS
LXF-289	MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH71epFKSzVyPUiuN\|U6PDNizszN	NH;hdYlUSU6JRWK=
MRK-nu-1	M33OeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\kW3JKSzVyPUiuN\|Y{ODRizszN	Mm\TV2FPT0WU
no-11	M1TOcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\FelNKSzVyPUiuOFcyOzNizszN	MYHTRW5ITVJ?
SNU-387	M3HyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDpZlVKSzVyPUiuOlMzPDZizszN	M{DFR3NCVkeHUh?=
Detroit562	Mn3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRThwN{W0OVUh\|ryP	MVnTRW5ITVJ?
SW954	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnEXm1KSzVyPUiuO\|Y5OzJizszN	NEfzXIVUSU6JRWK=
P12-ICHIKAWA	M3i2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUX6dI5UUUN3ME24Mlc5QTRizszN	M1jCOXNCVkeHUh?=
TE-9	MnHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRThwOEGwOlIh\|ryP	MlHTV2FPT0WU
NB13	MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnBR3hbUUN3ME24Mlg{Pzl4IN88US=>	MXLTRW5ITVJ?
BPH-1	M1nxfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrR[VBKSzVyPUiuPFUxQDFizszN	MYXTRW5ITVJ?
KMOE-2	NIroS5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nCN2lEPTB;OD64O\|g6OiEQvF2=	M3r2dnNCVkeHUh?=
RPMI-8402	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHe4S\|lKSzVyPUiuPFk6OjZizszN	MW\TRW5ITVJ?
OVCAR-3	NILzVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zMPWlEPTB;OD65O\|c{OiEQvF2=	NVPKSphnW0GQR1XS
NCI-H2196	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnmZpl5UUN3ME24Mlk5PjB4IN88US=>	MkLFV2FPT0WU
MZ7-mel	NXvLWoV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rvO2lEPTB;OT6wN\|Q3KM7:TR?=	NFvwPI5USU6JRWK=
GP5d	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF2x[YpKSzVyPUmuNFY{OTNizszN	MmW2V2FPT0WU
NCI-N87	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTlwNES3N\|Eh\|ryP	NY\vUodJW0GQR1XS
EW-16	M1zmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LO[GlEPTB;OT60OFg1QCEQvF2=	NV\afGgxW0GQR1XS
Calu-6	M17Xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTlwNEm3NFMh\|ryP	MVzTRW5ITVJ?
LC4-1	MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHWWVNKSzVyPUmuOlI2PyEQvF2=	MYnTRW5ITVJ?
CCRF-CEM	NYXoZpBiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTlwNki3OlYh\|ryP	MonvV2FPT0WU
BC-1	MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEn3d5pKSzVyPUmuO\|g6QSEQvF2=	M3jRcXNCVkeHUh?=
NCI-SNU-16	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\YSWlEPTB;OT63PVQ6PSEQvF2=	MV\TRW5ITVJ?
NCI-H28	MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{C2[mlEPTB;OT64OFk{OyEQvF2=	M1S3U3NCVkeHUh?=
SBC-1	M3LCVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\1OJQzUUN3ME2xNE4xPzJizszN	MmDuV2FPT0WU
TUR	M3\S[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmL5TWM2OD1zMD6xOlU4KM7:TR?=	NI\GSoJUSU6JRWK=
MDA-MB-231	NYDnTWpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInsN5lKSzVyPUGwMlIyOTRizszN	Mk\vV2FPT0WU
C3A	MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITYeXNKSzVyPUGwMlMyPzlizszN	NXPtTpA6W0GQR1XS
SW1990	M2W3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWL1VHkxUUN3ME2xNE4{OjhizszN	NGDXd2lUSU6JRWK=
NCI-H1993	NHfBbW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDMTWM2OD1zMD61Olk{KM7:TR?=	NE[xNpBUSU6JRWK=
SK-CO-1	NFroT4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHRTWM2OD1zMD63O\|ch\|ryP	M{PtdXNCVkeHUh?=
OAW-28	M3jvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTFyLkm4PFgh\|ryP	MUTTRW5ITVJ?
HN	NU\aZYx4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn:4TWM2OD1zMT6xNVMyKM7:TR?=	M3L0cHNCVkeHUh?=
NCI-H1304	M{nGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzQTWM2OD1zMT6xOVc3KM7:TR?=	MkfHV2FPT0WU
Daoy	NGG0fopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\1RphKSzVyPUGxMlQ{OzZizszN	NXjuVJV3W0GQR1XS
VA-ES-BJ	NHfTfodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPiTWM2OD1zMT63NVk2KM7:TR?=	M1uyWnNCVkeHUh?=
MCF7	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvGTWM2OD1zMT64NVI3KM7:TR?=	NInqXoFUSU6JRWK=
VM-CUB-1	NFXVUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVfJR\|UxRTFzLkmwPVEh\|ryP	MmjrV2FPT0WU
IPC-298	M4Ticmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTFzLkmzPFMh\|ryP	MV\TRW5ITVJ?
NCI-H2126	M1fWdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzHTWM2OD1zMj6wNlE5KM7:TR?=	MojNV2FPT0WU
OVCAR-8	NUnHV5RXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrCSXdkUUN3ME2xNk4yOTRzIN88US=>	MlTXV2FPT0WU
SJRH30	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYq3cY1SUUN3ME2xNk4zOjl7IN88US=>	Mm\1V2FPT0WU
DMS-53	NXfoWo1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjHcnRWUUN3ME2xNk4zPjR7IN88US=>	Mm\MV2FPT0WU
NCI-H322M	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\WPZVKSzVyPUGyMlM{PTdizszN	NUDWWIl3W0GQR1XS
RVH-421	M2DaPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLmTWM2OD1zMj60PVA1KM7:TR?=	MkTKV2FPT0WU
Raji	MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoOxTWM2OD1zMj62NVQh\|ryP	NYf0No97W0GQR1XS
MDA-MB-415	MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIK1NpdKSzVyPUGyMlY1PDRizszN	NVjYeIVSW0GQR1XS
EFE-184	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTF{LkexNFYh\|ryP	NHraZndUSU6JRWK=
BFTC-909	NI\VfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFP3eHRKSzVyPUGyMlkzPDdizszN	MVXTRW5ITVJ?
BHY	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnzTWJlUUN3ME2xN{4{OzlizszN	NGf3ZpZUSU6JRWK=
YKG-1	NF7nO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXHTWM2OD1zMz6zO\|Q6KM7:TR?=	MXXTRW5ITVJ?
EW-3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1;yOGlEPTB;MUOuO\|E3OyEQvF2=	M13jU3NCVkeHUh?=
HCC1143	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTF\|Lke0N\|ch\|ryP	NUXwWoR2W0GQR1XS
REH	NVPlXWhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XSc2lEPTB;MUOuPFk5OiEQvF2=	MUTTRW5ITVJ?
CESS	MlrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HvWWlEPTB;MUOuPVQ5QSEQvF2=	M1u3eXNCVkeHUh?=
EFM-19	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLhO4NKSzVyPUG0MlEyOTJizszN	Ml:5V2FPT0WU
U031	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXDTWM2OD1zND60NFg2KM7:TR?=	Mly1V2FPT0WU
ES1	M{jybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXRNW9vUUN3ME2xOE41QDVzIN88US=>	MlT3V2FPT0WU
HSC-3	NVz0[\|Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDLTWM2OD1zND62NlE2KM7:TR?=	NUDIRmtDW0GQR1XS
LOXIMVI	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljETWM2OD1zND63NFY5KM7:TR?=	M1TMfXNCVkeHUh?=
A388	NYe2[XV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIX0eVBKSzVyPUG0Mlc2PTZizszN	Mkf4V2FPT0WU
KP-N-YS	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLE[pVLUUN3ME2xOE44PzNizszN	MXrTRW5ITVJ?
Capan-2	MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPpZnA{UUN3ME2xOE44QDZizszN	NI\pdW1USU6JRWK=
SKG-IIIa	NV\rbldkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnpVnhIUUN3ME2xOE45QDZ{IN88US=>	NWfwO\|BxW0GQR1XS
HEL	NXfRN4FwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moe4TWM2OD1zND64PVk4KM7:TR?=	MnraV2FPT0WU
BEN	M3PvRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTLNllKSzVyPUG0Mlk4PjZizszN	NUDrdYVDW0GQR1XS
MC116	NY\xclduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGe0UnFKSzVyPUG1MlE2QTlizszN	NFzjSJpUSU6JRWK=
IGROV-1	MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzIW5dmUUN3ME2xOU4zOzF5IN88US=>	M1rPbHNCVkeHUh?=
NCI-H1648	MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUj1b3ZNUUN3ME2xOU42OzB3IN88US=>	NUDyPZlCW0GQR1XS
ABC-1	MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTF3LkiwN\|Mh\|ryP	NYLifHFwW0GQR1XS
EW-18	NFK1U4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrz[G1KSzVyPUG1Mlk6PzlizszN	M1TSd3NCVkeHUh?=
BC-3	NIflSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVruPGNXUUN3ME2xOk4xPTZ{IN88US=>	M1fTW3NCVkeHUh?=
NCI-H1437	MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHG2U4pKSzVyPUG2MlA3PjdizszN	MlLkV2FPT0WU
SCC-15	NH7xUWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7wWYVKSzVyPUG2MlI5OjVizszN	MWLTRW5ITVJ?
TT	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3q1[2lEPTB;MU[uOVg5QCEQvF2=	NEDnPXBUSU6JRWK=
KINGS-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVjt[VU3UUN3ME2xOk45Ojd\|IN88US=>	NGnvVI5USU6JRWK=
C32	NI\wUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;ISVJKSzVyPUG2Mlk4OTdizszN	MnG0V2FPT0WU
SBC-5	Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPQTWM2OD1zNz6xOFc6KM7:TR?=	Mn[xV2FPT0WU
NB1	M17Xemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnLfIV2UUN3ME2xO{4{OTh6IN88US=>	NIPze5dUSU6JRWK=
EB-3	NY\lcm9DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGK1OZBKSzVyPUG3MlU4PiEQvF2=	MkL4V2FPT0WU
NCI-H748	MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDRTWM2OD1zNz63NFM2KM7:TR?=	NYH0cINJW0GQR1XS
IST-SL1	MkPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13rXmlEPTB;MUeuO\|UzPiEQvF2=	NE\BN4RUSU6JRWK=
WM-115	MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXn3NYFrUUN3ME2xO{45ODh3IN88US=>	NV\BWnBRW0GQR1XS
NCI-H226	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFmxcZRKSzVyPUG3Mlk2PDZizszN	NFj3OlVUSU6JRWK=
CAL-33	Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\LdG5KSzVyPUG4MlI4QDFizszN	Mlm2V2FPT0WU
SCC-4	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLrUnhKSzVyPUG4MlMzOjlizszN	M3Tk[3NCVkeHUh?=
RMG-I	NHfHcJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTF6Lk[5OFch\|ryP	MVPTRW5ITVJ?
KOSC-2	M3juN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3iN5ZKSzVyPUG4Mlc4PDZizszN	NEPSc\|ZUSU6JRWK=
A2058	MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWPJR\|UxRTF6LkiyOVUh\|ryP	MnKwV2FPT0WU
HCC70	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTF7LkO4PVQh\|ryP	MX3TRW5ITVJ?
C2BBe1	MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX[xdJIzUUN3ME2xPU41OTR6IN88US=>	M2r6[3NCVkeHUh?=
NCI-H650	MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{X6NGlEPTB;MUmuOVg6QSEQvF2=	MlPNV2FPT0WU
CAL-72	M2H5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HkVGlEPTB;MUmuOlc{PyEQvF2=	MmKyV2FPT0WU
L-363	NFvqSopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjxcHlKSzVyPUKwMlAzOTJizszN	MVLTRW5ITVJ?
SNU-423	Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjSU4RKSzVyPUKwMlExPDNizszN	M{nOO3NCVkeHUh?=
PLC-PRF-5	MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm[yTWM2OD1{MD6zPVA3KM7:TR?=	NIDkNJlUSU6JRWK=
SW1463	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTJyLkS1NlUh\|ryP	NXPtXpVwW0GQR1XS
769-P	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLGTWM2OD1{MD62O\|Y6KM7:TR?=	MnjoV2FPT0WU
DMS-79	M2Gx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\6VnlCUUN3ME2yNE45PDlizszN	MkH4V2FPT0WU
Saos-2	NF[wXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTj[Wd3UUN3ME2yNE46PTV4IN88US=>	NH7LXYtUSU6JRWK=
CHP-126	NHzMXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\mb2lEPTB;MkGuOFQ3OiEQvF2=	MYXTRW5ITVJ?
SW837	NVnLVYExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrGVZFWUUN3ME2yNU41QTN7IN88US=>	MoDtV2FPT0WU
SHP-77	NX;JdoVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLY[m9xUUN3ME2yNU43OTJ{IN88US=>	NXzuNGc2W0GQR1XS
DB	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfDWGtiUUN3ME2yNU43OTR{IN88US=>	MoHTV2FPT0WU
ES5	NG\XcGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXe5fWJGUUN3ME2yNU43QDZ2IN88US=>	MofWV2FPT0WU
COR-L23	NUm2O\|N{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTJzLkiwOVEh\|ryP	Moe4V2FPT0WU
KU-19-19	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zhRmlEPTB;MkGuPFk5OiEQvF2=	NEHyRlRUSU6JRWK=
T84	NX7hbY9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVe1ZYEzUUN3ME2yNU46QDF7IN88US=>	M4TRSXNCVkeHUh?=
NCI-H630	NYXyNWRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4O1SGlEPTB;MkKuOVM3OyEQvF2=	NIjL[YNUSU6JRWK=
LU-165	MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\WSXFKSzVyPUKyMlU2PCEQvF2=	M1jyNHNCVkeHUh?=
COLO-792	NYDEZ29[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rYVmlEPTB;MkKuO\|EyOSEQvF2=	NVW1Ro9tW0GQR1XS
CAL-62	NXjhbFJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGr2c2NKSzVyPUKyMlc2OTdizszN	NInHenpUSU6JRWK=
HCE-T	NFHLWm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInwNlFKSzVyPUKyMlg3ODZizszN	MoixV2FPT0WU
BB65-RCC	M{XCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvGfIVuUUN3ME2yN{4xOzR2IN88US=>	M1rWNHNCVkeHUh?=
SiHa	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLxWndKSzVyPUKzMlM6PjhizszN	Ml3FV2FPT0WU
NCI-H2081	M3LRbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV3JR\|UxRTJ2LkC2OFEh\|ryP	M1fpeXNCVkeHUh?=
U251	M2i5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrOSVdDUUN3ME2yOE4xPjZ6IN88US=>	M2fNVXNCVkeHUh?=
LoVo	M1HadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHOTWM2OD1{ND65NlgzKM7:TR?=	MlS2V2FPT0WU
GCIY	MmflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1q4[WlEPTB;MkWuNlg4PyEQvF2=	MXvTRW5ITVJ?
NUGC-3	MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;5cGlEPTB;MkWuN\|MyPiEQvF2=	NXPqfnJWW0GQR1XS
LNCaP-Clone-FGC	M2PJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrhRpZKSzVyPUK1MlM1QThizszN	NFPMfmxUSU6JRWK=
PA-1	NX3nT29yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnyRXNOUUN3ME2yOU43QDN\|IN88US=>	M3\E[3NCVkeHUh?=
OE33	NYj1WItsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnP1TWM2OD1{NT62PFU{KM7:TR?=	MXXTRW5ITVJ?
HT-29	NFfj[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTJ3Lke4O\|kh\|ryP	M2jIcXNCVkeHUh?=
RCM-1	NEPOPHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnTTWM2OD1{NT65OlU3KM7:TR?=	NIHoVIRUSU6JRWK=
NCI-H1522	NWHZc2c1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGKxfYhKSzVyPUK1Mlk6OTFizszN	MoraV2FPT0WU
LB373-MEL-D	NITOc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jhUmlEPTB;Mk[uNVcxQCEQvF2=	M2jld3NCVkeHUh?=
NCI-H1436	MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLibYxDUUN3ME2yOk4zPzN6IN88US=>	NV\SNlA5W0GQR1XS
COLO-824	NXnwbYwyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jBdGlEPTB;Mk[uOFAxOiEQvF2=	MnvUV2FPT0WU
CP50-MEL-B	NHrKPXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jDVmlEPTB;Mk[uOVY4PSEQvF2=	MkfuV2FPT0WU
EGI-1	M2DYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;BTWM2OD1{Nz6yOlk5KM7:TR?=	M1TsR3NCVkeHUh?=
LAN-6	NVrxUoVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTJ5LkO1PVgh\|ryP	M13NN3NCVkeHUh?=
GAK	NWrHcVdRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7hOWFKSzVyPUK3MlQzOjVizszN	MV\TRW5ITVJ?
MDA-MB-175-VII	M1:4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLSOWhzUUN3ME2yO{42ODV\|IN88US=>	MoLzV2FPT0WU
JVM-2	NITNU4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnJTHBKSzVyPUK3MlY3OjJizszN	MoG3V2FPT0WU
UACC-257	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTJ5Lk[4O\|gh\|ryP	NELSNpdUSU6JRWK=
SW1783	MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7uTWM2OD1{Nz63O\|g{KM7:TR?=	MnzXV2FPT0WU
HT-3	MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfwW3NKSzVyPUK4MlIyPjZizszN	MVLTRW5ITVJ?
RL	NU\5fZJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4THT2lEPTB;MkiuOVkyOSEQvF2=	MmHWV2FPT0WU
TK10	NHPFUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrUTWM2OD1{OD62OVM2KM7:TR?=	NHi4XWlUSU6JRWK=
HT55	NWfXfVlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTxZ2ZKSzVyPUK5MlA2PjVizszN	NXu5So5CW0GQR1XS
BT-20	MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HvUWlEPTB;MkmuNFU5PiEQvF2=	NEDNOZBUSU6JRWK=
TGBC24TKB	MlfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLETWM2OD1{OT6xPFMyKM7:TR?=	MWPTRW5ITVJ?
HSC-2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGOwcpFKSzVyPUK5MlMxODFizszN	NFfqeWZUSU6JRWK=
COLO-205	NH\mR3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13Y[2lEPTB;MkmuN\|k1PCEQvF2=	M1LaWHNCVkeHUh?=
GT3TKB	NXrsN\|YyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmK1TWM2OD1{OT62PFc4KM7:TR?=	NYq4[m1SW0GQR1XS
T47D	M2Tmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX3abVgzUUN3ME2yPU45PTh{IN88US=>	MnjpV2FPT0WU
OMC-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTNyLkG5NVkh\|ryP	M3zhW3NCVkeHUh?=
PFSK-1	MmftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PKfmlEPTB;M{GuNlY2QSEQvF2=	M1TxVnNCVkeHUh?=
JEG-3	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjBUpNyUUN3ME2zNU4{PTZzIN88US=>	M3;pbXNCVkeHUh?=
RD	NWnkT49WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHyfVBDUUN3ME2zNU42OTF3IN88US=>	M3TE[XNCVkeHUh?=
NCI-H64	MlLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvLTWM2OD1\|Mj60NVc6KM7:TR?=	MW\TRW5ITVJ?
DMS-114	MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LCSGlEPTB;M{KuOFE5OiEQvF2=	M3\wOnNCVkeHUh?=
NCI-H661	NYTCb5dKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37wSWlEPTB;M{KuOlUxOSEQvF2=	MlHkV2FPT0WU
CAL-148	M136b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYnHZm9iUUN3ME2zNk43PjZ3IN88US=>	MlT4V2FPT0WU
HuP-T3	NVHob4s{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWGxTlRPUUN3ME2zNk46OzN6IN88US=>	NELzXFBUSU6JRWK=
ES4	MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTN\|LkG3NFUh\|ryP	MnXSV2FPT0WU
Ca9-22	NYG3R2JET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPNTWM2OD1\|Mz60OlAyKM7:TR?=	M{PTVXNCVkeHUh?=
LP-1	MlvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTTeFlFUUN3ME2zOE4xQSEQvF2=	Ml3NV2FPT0WU
AU565	NYHaUVcxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\XTWM2OD1\|ND61NFY6KM7:TR?=	MUHTRW5ITVJ?
MDA-MB-453	NYHjU4VOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvlTWM2OD1\|NT6xOFI3KM7:TR?=	MWXTRW5ITVJ?
SNU-C1	MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoO0TWM2OD1\|NT6xO\|Eh\|ryP	NVPUelMxW0GQR1XS
SW13	NF7SdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\F[2lEPTB;M{WuOFA4PiEQvF2=	M3zGWHNCVkeHUh?=
NCI-H2122	NF;ZRZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInqbFRKSzVyPUO1MlU2QThizszN	Ml;CV2FPT0WU
NCI-H1395	M4L1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHZUo9KSzVyPUO1MlY3QTFizszN	MYjTRW5ITVJ?
J-RT3-T3-5	Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XnTGlEPTB;M{[uNFI6PCEQvF2=	MmXPV2FPT0WU
COR-L279	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjSWFJZUUN3ME2zOk4yQThzIN88US=>	M3X1U3NCVkeHUh?=
ATN-1	NF73OXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnqTWM2OD1\|Nj64OVE3KM7:TR?=	NYrqXohUW0GQR1XS
HCC2998	MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;MV2VKSzVyPUO2Mlg2PzFizszN	NYKxelYyW0GQR1XS
UM-UC-3	M1fnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTN4Lki2O\|Uh\|ryP	MoDQV2FPT0WU
DV-90	M4TyZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHm[nI5UUN3ME2zOk46ODZ5IN88US=>	Mm\xV2FPT0WU
ES8	NWjaRY5UT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M32yZ2lEPTB;M{[uPVMyQCEQvF2=	MULTRW5ITVJ?
YAPC	NW\wVlVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;MfWQ{UUN3ME2zOk46PjV2IN88US=>	NFXISXlUSU6JRWK=
HCC1599	M3rhfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfHd5hKSzVyPUO3MlE3OThizszN	MWHTRW5ITVJ?
UMC-11	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvwTWM2OD1\|Nz6yOVA{KM7:TR?=	MXvTRW5ITVJ?
THP-1	M17qRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTN5LkK4Olgh\|ryP	NV7vZmc4W0GQR1XS
OCUB-M	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2i1XmlEPTB;M{euNlg6OSEQvF2=	MXHTRW5ITVJ?
NCI-H1693	NG\ZdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HleGlEPTB;M{euN\|I{OyEQvF2=	NX3wZ\|dyW0GQR1XS
NCI-H345	M2DVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TBTGlEPTB;M{euN\|YzPCEQvF2=	M2KzXXNCVkeHUh?=
COLO-800	NYTpe2pZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILxTHRKSzVyPUO3MlU3PyEQvF2=	MmPLV2FPT0WU
COLO-320-HSR	M4ryNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWT6TmpDUUN3ME2zPE4{PDl{IN88US=>	NI\XeGVUSU6JRWK=
NCI-H596	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPqTWhiUUN3ME2zPE41PDh7IN88US=>	NWnMb5NUW0GQR1XS
NCI-H187	NWe5dlM3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3rTWM2OD1\|OD63N\|Q1KM7:TR?=	MmjqV2FPT0WU
ECC4	MkLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nyNmlEPTB;M{muNFgyPCEQvF2=	NH[ybZpUSU6JRWK=
KP-4	MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fiZmlEPTB;M{muNVI{PSEQvF2=	MVrTRW5ITVJ?
NCI-H2227	M4PN[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\IbmVKSzVyPUO5MlM6PDlizszN	NX3ob21{W0GQR1XS
22RV1	MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXhb4tKSzVyPUO5Mlg{QThizszN	NH3xOGtUSU6JRWK=
SAS	NUP3N5RTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH3DXHpKSzVyPUSwMlA6PiEQvF2=	MXHTRW5ITVJ?
PANC-10-05	MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHhTWM2OD12MD6xPFI5KM7:TR?=	MlnSV2FPT0WU
MDA-MB-468	M2\YfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;ITWM2OD12MD61N\|Q3KM7:TR?=	NYC5O2NFW0GQR1XS
RPMI-7951	NInuNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;tUVRKSzVyPUSxMlIxPzVizszN	NW\0N4EyW0GQR1XS
BB49-HNC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLPTWM2OD12MT6yNVc6KM7:TR?=	MYXTRW5ITVJ?
23132-87	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHYTWM2OD12MT6yO\|MzKM7:TR?=	M{HzNnNCVkeHUh?=
HCC1569	MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fZRWlEPTB;NEGuNlg5PSEQvF2=	M3u2RXNCVkeHUh?=
CP66-MEL	NVr2PWR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPjSZVKSzVyPUSyMlE5QDZizszN	MkH5V2FPT0WU
K-562	MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HYOWlEPTB;NEKuNlg2PCEQvF2=	MWTTRW5ITVJ?
OCI-AML2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvkOJJMUUN3ME20Nk45QTd2IN88US=>	NF7xUnlUSU6JRWK=
SW756	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknETWM2OD12Mz6wN\|g5KM7:TR?=	MXrTRW5ITVJ?
M14	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmn4TWM2OD12Mz6zNVg6KM7:TR?=	NF76ZWtUSU6JRWK=
NCI-H1623	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTSOmwxUUN3ME20N{41PjRizszN	NIf5NHFUSU6JRWK=
KNS-81-FD	M{frOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTR\|Lke2NkDPxE1?	M13EeHNCVkeHUh?=
TGBC1TKB	NFPFfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1q1cGlEPTB;NEOuPVA6QSEQvF2=	M{fobnNCVkeHUh?=
RERF-LC-MS	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn61TWM2OD12Mz65NlgyKM7:TR?=	NIS2SpNUSU6JRWK=
PC-3	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF:5PVdKSzVyPUS0MlQ{PDdizszN	NF7BcVJUSU6JRWK=
HuP-T4	NVmwfWpPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTR2LkS0O\|Qh\|ryP	MorUV2FPT0WU
NCI-H510A	M3nEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTR2LkewPEDPxE1?	NIHETINUSU6JRWK=
LB2518-MEL	NYjvUWVxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTR2Lke5N\|ch\|ryP	NHTENFRUSU6JRWK=
TE-5	NVvTflBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2DJW2lEPTB;NEWuPVU5OSEQvF2=	MV3TRW5ITVJ?
EW-24	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEO2SmxKSzVyPUS2MlE4OjNizszN	M{Dme3NCVkeHUh?=
LB647-SCLC	NFrBU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TnXGlEPTB;NE[uNlE2PSEQvF2=	NXX0PJJFW0GQR1XS
NCI-H524	Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvyRXZKSzVyPUS2MlcyQDVizszN	MlTsV2FPT0WU
EW-11	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTR4LkmzO\|Mh\|ryP	NVHpdVQzW0GQR1XS
KALS-1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTR5LkKwOlYh\|ryP	MYrTRW5ITVJ?
BT-474	NFX3OFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrpUoZKSzVyPUS3MlQzOTZizszN	NYrUcXlqW0GQR1XS
SK-N-AS	NEHkbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELjbVlKSzVyPUS3Mlg5QCEQvF2=	NF;GUGRUSU6JRWK=
HCC2157	NULVOHB2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTR6LkC3OkDPxE1?	MWnTRW5ITVJ?
HCC1954	NFj5cFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYL1doZvUUN3ME20PE4yPzB2IN88US=>	M3;rOXNCVkeHUh?=
FADU	NWLjVZhMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\SV21[UUN3ME20PE4{ODNzIN88US=>	NHrMWpRUSU6JRWK=
S-117	MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPBb5hKSzVyPUS4MlM5OTVizszN	M1\vOnNCVkeHUh?=
LS-1034	NVm3PJdpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTR6LkewOlch\|ryP	NGGxWWlUSU6JRWK=
CAMA-1	Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3ZUlI4UUN3ME20PU42PTR\|IN88US=>	NYnIPHY6W0GQR1XS
LU-134-A	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXjT4xKSzVyPUS5MlgxQDVizszN	NFzy[XFUSU6JRWK=
NCI-H1838	M3nDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rUVWlEPTB;NEmuPFA5PyEQvF2=	M4LRNnNCVkeHUh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ

Methods	Test Index	PMID
Western blot	pSrc / Src / pPlcg / Plcg / pStat5 / Stat5 ; PubMed: 22781593 Leukemia In (B) inhibition of Src, Plcg and Stat5 was seen in MLNAF cell lines treated with Ponatinib; ZNF112 expresses ZMYM2–FGFR1, CEP2A and CEP5A cells express CEP110–FGFR1 and BBC2 expresses BCR–FGFR1. pFGFR1(pY20) / FGFR1; PubMed: 22781593 Leukemia Western blot analysis, using various antibodies specific for downstream targets of FGFR1, demonstrates that Ponatinib inhibits the activation of Plcg and Src as a result of inhibiting the FGFR1 fusion kinase in human KG1 cells. cleaved caspase-3 / cleaved caspase-7 / BAX / Bcl-2; PubMed: 30959969 Molecules Western blot analysis of cleaved caspase-3, cleaved caspase-7, Bax, Bcl-2, and β-Tubulin (control) in treated cells. p-Rb(S807/811) / Rb / CDK4 / CDK6 / Cyclin D1 / CDK2 / Cyclin E1; PubMed: 30959969 Molecules Western blot analysis of Rb/p-Rb, CDK4, CDK6, Cyclin D1, CDK2, Cyclin E1, and β-Tubulin (control) in the SK-Hep-1 and SNU-423 cells treated with ponatinib. RAD51; PubMed: 30959969 Molecules The effect of ponatinib on the concentration of Rad51 in SK-Hep-1 and SNU-423 cells. p-MEK / MEK / p-ERK / ERK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Mek and Erk. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. c-Jun / p-JNK(T183/Y185) / JNK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of JNK and c-Jun. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-p38 MAPK / p38 MAPK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of p38. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-JAK2 / JAK2 / p-STAT3 / STAT3; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Jak2, and Stat3. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. PI3K p85 / p-PI3K / p-PDK1 / PDK1 / p-mTOR / mTOR; PubMed: 30959969 Molecules Effects of ponatinib on the protein concentration and phosphorylation of PI 3-kinase, PDK1, Akt, and mTOR in HCC cells. p-PDGFRα / PDGFRα; PubMed: 24472312 Mol Cancer Ponatinib inhibited phosphorylation of PDGFRα in a concentration-dependent manner. EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed to escalating concentrations of ponatinib for 24 h. PARP / Caspase-3 / Active Caspase-3; PubMed: 24472312 Mol Cancer The concentration- (for 24 h) and time-dependent (1 nM for EOL-1, 300 nM for BaF3-WT and -T674I FIP1L1-PDGFRα cells) cleavage of PARP and caspase-3 triggered by ponatinib was analyzed by immunoblotting. AIF / Cyto C ; PubMed: 24472312 Mol Cancer Ponatinib elicited release of AIF and cytochrome c into the cytosol. Cells were treated with 1 nM ponatinib for the indicated durations and the cytosolic fraction was extracted with digitonin buffer. Levels of AIF and Cytochrome c (Cyto c) were detected by immunoblotting. Mcl-1 / Survivin / Bcl-Xl / XIAP / Bax / Bcl-2 / Bim; PubMed: 24472312 Mol Cancer Immunoblotting of apoptosis-related proteins in CEL cells after treatment for 24 h. β-catenin ; PubMed: 24472312 Mol Cancer Ponatinib concentration-dependently lowered β-catenin. EOL-1 cells were incubated with ponatinib for 24 h, and cytoplasmic and nuclear extracts were determined by immunoblotting. β-catenin; PubMed: 24472312 Mol Cancer Analysis of β-catenin localization. EOL-1 cells were pretreated with 1 nM ponatinib for 24 h, immunofluorescence analysis was performed with anti-β-catenin. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). ABL; PubMed: 19878872 Cancer Cell In vitro [γ-32P]-ATP autophosphorylation of full-length (A) ABL or (B) ABLT315I kinase treated with AP24534, imatinib, nilotinib, or dasatinib. After incubation of tyrosine-dephosphorylated enzyme with the indicated inhibitor in the presence of [γ-32P]-ATP and separation by SDS-PAGE, signal intensity was measured by autoradiography.	22781593 30959969 24472312 19878872
Growth inhibition assay	Cell viability; PubMed: 30174789 Oncotarget (A) Effect of Ponatinib on basal viability of HUVECs. The cells were treated with Ponatinib at indicated concentrations or 0.1% DMSO (vehicle control) for 24 h.	30174789

体内試験

In a mouse xenograft model of Ba/F3 cells expressing native Bcr-Abl, AP24534 (2.5 mg/kg and 5 mg/kg) prolongs mice median survival. In the xenograft model of Ba/F3 Bcr-Abl^T315I, AP24534 (10 mg/kg–50 mg/kg) significantly suppresses tumor growth. AP24534 (30 mg/kg) decreases the phosphorylated Bcr-Abl and phosphorylated CrkL levels in the tumors. ^[2]

お薦めの試験操作（参考用のみ）

キナーゼ試験：^[1]	- 合併 Peptide substrate phosphorylation assays with GST-Abl kinase domains: The effect of AP24534 (0-320 nM) on GST-Abl kinase activity is assessed by using a synthetic peptide substrate (Abltide: EAIYAAPFAKKK). Assays are carried out at 30 °C for 15 min in 25 μL reaction mixture: 8 mM MOPS (pH 7), 0.2 mM EDTA, 50 μM Abltide, 30 mM MgCl₂, 10 mM β-glycerol phosphate, 1 mM EGTA, 0.002% Brij-35, 0.4 mM DTT, 0.2 mg/mL BSA, 0.4 mM sodium orthovanadate, 10 nM WT or mutant GST-Abl kinase, and 100 µM ATP/γ-³²[P]ATP (5000 cpm/pmol). Reactions are terminated by transferring a portion of the reaction mixture onto a p81 phosphocellulose filter and immersing in 0.75% phosphoric acid. Filters are washed 3 times in 0.75% phosphoric acid, rinsed in acetone, and air dried; phosphate incorporation is determined by scintillation counting. All results are corrected for background binding to the filters, as determined by omitting peptide substrate from the kinase reaction. Time course experiments to establish the linear range of enzymatic activity precedes kinase assays.
細胞試験： ^[2]	- 合併細胞株： Ba/F3 cells expressing Bcr-Abl or a range of single mutations in the kinase domain of Bcr-Abl 濃度： 0-625 nM 反応時間： 72 hours 実験の流れ： Ba/F3 cell lines are distributed in 96-well plates (4 × 10³ cells/well) and incubated with AP24534 for 72 hours. Proliferation is measured using a methanethiosulfonate (MTS)-based viability assay (CellTiter96 Aqueous One Solution). All values are normalized to the control wells with no drug. IC50 values are reported as the mean of three independent experiments performed in quadruplicat (参考用のみ)
動物試験：^[1]	- 合併動物モデル： Mouse xenograft models of Ba/F3 cells expressing Bcr-Abl or Bcr-Abl^T315I 投薬量： 2.5 mg/kg and 5 mg/kg for Ba/F3 Bcr-Abl; 2.5 mg/kg–50 mg/kg for Ba/F3 Bcr-Abl^T315I 投与方法： Oral gavage once daily (参考用のみ)

参考

- 合併

溶解度 (25°C)

体外	DMSO	30 mg/mL (56.33 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	左から（NMPから）右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ): 1% CMC Na 混合させたのち直ちに使用することを推奨します。	30mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報 Ponatinib (AP24534) SDFをダウンロードする

分子量	532.56
化学式	C₂₉H₂₇F₃N₆O
CAS No.	943319-70-8
Storage	3 years-20°C powder 2 years-80°C in solvent
別名	N/A
Smiles	CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5

投与溶媒組成計算器(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量

mg/kg

動物平均体重

投与体積（動物毎）

動物数

匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO+ % + % Tween 80+ % ddH₂O

計算リセット

計算結果:

投与溶媒濃度： mg/ml；

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL，注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。）

投与溶媒調製方法：μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

便利ツール

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

質量

濃度

体積

分子量
=

×

×

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA（製品ページで利用可能な）。

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます：

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます：C1V1 = C2V2 ( 入力出力 )

C1

V1

C2

V2
×

=

×

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA（オンラインで利用できる）で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

連続希釈剤
初めの濃度：
稀釈倍数：

計算結果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください：

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

臨床試験 (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04554459	Not yet recruiting	Drug: Ponatinib 15 MG Oral Tablet	Acute Lymphoblastic Leukemia Adult\|Ph+ ALL\|Newly Diagnosed	Institute of Hematology and Blood Transfusion Czech Republic\|CZECRIN - Czech Clinical Research Infrastructure Network	October 30 2020	Phase 2
NCT04160546	Recruiting	Drug: Ponatinib 15 MG\|Drug: Acetylsalicylic acid 100 MG	Chronic Myeloid Leukemia Chronic Phase	Fundacion CRIS de Investigación para Vencer el Cáncer\|Incyte Biosciences UK\|Apices Soluciones S.L.	January 17 2020	Phase 2
NCT03934372	Recruiting	Drug: Ponatinib	Acute Myeloid Leukemia\|Accelerated Phase Chronic Myeloid Leukemia\|Blast Phase Chronic Myeloid Leukemia\|Chronic Phase Chronic Myeloid Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphocytic Leukemia\|Leukemia\|Lymphoma\|Solid Tumors	Incyte Biosciences International Sàrl\|Incyte Corporation	January 29 2020	Phase 1\|Phase 2
NCT04070443	Recruiting	Drug: Ponatinib\|Drug: Imatinib	Philadelphia Chromosome Positive CML\|BCR-ABL Positive Chronic Myelogenous Leukemia	Centre Leon Berard	November 13 2019	Phase 2
NCT03895671	Recruiting	Drug: Ponatinib\|Drug: Azacitidine	CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE\|CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS	Versailles Hospital	June 19 2019	Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

よくある質問（FAQ）

質問1：
Is the pre-solubilized inhibitor suitable for in vivo whole animal studies? Whether the solvent contains any non-DMSO stabilizer?
回答：
Our 10mM Ponatinib in DMSO solution is in pure DMSO and there is not other stabilizer added. You can use it for animal study. The vehicle we suggest for Ponatinib is: 30% PEG400/0.5% Tween80/5% Propylene glycol. It is a milky suspension used for oral gavage.

Bcr-Ablシグナル伝達経路

Bcr-Abl Inhibitors with Unique Features

Selective Bcr-Abl Inhibitor

Nilotinib (AMN-107) : Bcr-Abl-selective, IC50<30 nM.
Most Potent Bcr-Abl Inhibitor

GZD824 : Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.
FDA-approved Bcr-Abl Inhibitor

Dasatinib : Approved by FDA for CML and Ph+ ALL.
Newest Bcr-Abl Inhibitor

GZD824 : Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

相関Bcr-Abl製品

PX-478 2HCl

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Defactinib (VS-6063)

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
SU6656

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
Imatinib (STI571) Mesylate

Imatinib Mesylate (STI571, CGP-57148B) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively. Imatinib Mesylate (STI571) induces autophagy.
Nilotinib (AMN-107)

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells. Nilotinib induces autophagy through AMPK activition.

Features:A selective inhibitor of native and mutant Bcr-Abl.
Bafetinib (INNO-406)

Bafetinib (INNO-406, NS-187) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. Phase 2.

Features:Dual Bcr-Abl/Lyn inhibitor.
Degrasyn (WP1130)

Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT). Degrasyn (WP1130) induces apoptosis and blocks autophagy.

Features:WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.

研究分野別

製品類型

Ponatinib (AP24534)

文献中Selleckの製品使用例(132)

製品安全説明書

Bcr-Abl阻害剤の選択性比較

生物活性

お薦めの試験操作（参考用のみ）

参考

溶解度 (25°C)

化学情報 Ponatinib (AP24534) SDFをダウンロードする

投与溶媒組成計算器(クリア溶液)

便利ツール

モル濃度計算器

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

希釈計算器

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

連続希釈計算器方程式

連続希釈剤

計算結果

分子量计算器

総分子量：g/mol

モル濃度計算器

臨床試験 (data from https://clinicaltrials.gov, updated on 2020-01-06)

技術サポート

よくある質問（FAQ）

Bcr-Ablシグナル伝達経路

Bcr-Abl Inhibitors with Unique Features

相関Bcr-Abl製品